Adverse Events During Perampanel Adjunctive Therapy in Intractable Epilepsy

摘要

Background and PurposePerampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either rapid or slow dose titration on adverse events remain to be elucidated.